ABVC Biopharma Ev To Operating Cash Flow Over Time
| ABVC Stock | USD 0.51 0.01 1.92% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ABVC Biopharma Performance and ABVC Biopharma Correlation. ABVC |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share 0.017 | Quarterly Revenue Growth 18.175 | Return On Assets (0.45) | Return On Equity (3.20) |
The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ABVC Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ev To Operating Cash Flow Analysis
Compare ABVC Biopharma and related stocks such as Indaptus Therapeutics, Pasithea Therapeutics, and Better Therapeutics Ev To Operating Cash Flow Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INDP | (2.2687) | (2.2687) | (2.2687) | (2.2687) | (2.2687) | (2.2687) | (4.0663) | (1.6969) | (5.0146) | (0.3078) | (1.5255) | 1.3858 | (0.1861) | (0.1193) | (0.13) |
| KTTA | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | (1.3 K) | 3.8569 | 1.0996 | 515 | 540 |
| FBRX | (11.2321) | (11.2321) | (11.2321) | (11.2321) | (11.2321) | (11.2321) | (8.8591) | (4.0027) | (4.354) | (6.7465) | (11.3539) | 0.7287 | 2.8976 | (0.4869) | (0.51) |
| ALRN | 0.4128 | 0.4128 | 0.4128 | 0.4128 | 0.1221 | (9.7444) | (6.4713) | (3.2432) | (0.2538) | (0.5205) | (1.4457) | (1.9601) | (0.2251) | 0.1635 | 0.17 |
| AKTX | (212) | (212) | (93.316) | (60.4669) | (86.115) | (484) | (65.9543) | (33.7677) | (21.7594) | (2.1466) | (2.6185) | (2.9194) | (0.7484) | (0.6953) | (0.73) |
| ADTX | (2.1 K) | (2.1 K) | (2.1 K) | (2.1 K) | (2.1 K) | (2.1 K) | (2.1 K) | (2.1 K) | (2.1 K) | (2.3 K) | (148) | (18.2343) | (3.8528) | (5.2918) | (5.56) |
| RNXT | (21.8424) | (21.8424) | (21.8424) | (21.8424) | (21.8424) | (21.8424) | (21.8424) | (21.8424) | (21.8424) | (21.8424) | (18.1066) | (4.7411) | (1.6833) | (2.1829) | (2.29) |
| ANEB | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (28.5812) | (19.6505) | (4.9238) | (8.1709) | (8.58) |
| SABS | (479) | (479) | (479) | (479) | (479) | (479) | (479) | (479) | (479) | (479) | 25.3114 | 49.7678 | 4.4052 | 0.5044 | 0.53 |
| MNPR | (2.2 K) | (2.2 K) | (2.2 K) | (2.2 K) | (2.2 K) | (2.2 K) | (1.2 K) | (522) | (476) | (287) | (68.3326) | (24.5818) | (19.718) | (2.2147) | (2.33) |
| ELDN | (37.8465) | (37.8465) | (37.8465) | (21.5275) | 0.4687 | (4.1721) | 0.4493 | (0.1177) | (0.1208) | 0.1171 | 6.0281 | 0.6471 | 0.8124 | (1.1 K) | (1.1 K) |
| NTRB | (232) | (232) | (232) | (232) | (232) | (232) | (232) | (604) | (162) | (97.6228) | (355) | (8.8961) | (9.7341) | (5.8139) | (6.1) |
| QNRX | (0.2744) | (0.2744) | (0.2744) | (0.2744) | (0.2744) | (0.2744) | (3.3084) | (7.0769) | (1.3422) | 0.1622 | (20.0507) | (130) | (0.4747) | (0.2576) | (0.27) |
| LGVN | (21.9833) | (21.9833) | (21.9833) | (21.9833) | (21.9833) | (21.9833) | (21.9833) | (21.9833) | (21.9833) | (50.5946) | (54.2595) | (21.3563) | (4.2682) | (1.4026) | (1.47) |
| VRAX | (279) | (279) | (279) | (279) | (279) | (279) | (279) | (279) | (279) | (279) | (351) | (256) | 0.4341 | 0.3026 | 0.32 |
ABVC Biopharma and related stocks such as Indaptus Therapeutics, Pasithea Therapeutics, and Better Therapeutics Ev To Operating Cash Flow description
A valuation metric comparing the company's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows.My Equities
My Current Equities and Potential Positions
| ABVC Biopharma | ABVC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.51
Check out ABVC Biopharma Performance and ABVC Biopharma Correlation. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
ABVC Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.